Key result
Costunolide significantly attenuated doxorubicin-induced cardiorenal toxicity, oxidative stress, inflammation, and apoptosis in rats.
Why the study?
Doxorubicin-induced cardiorenal toxicity limits its clinical usefulness in cancer patients, prompting evaluation of costunolide's protective effects.
Does costunolide prevent doxorubicin-induced cardiorenal toxicity in rats?
Population
Rats
Comparison
Oral costunolide for 4 weeks with weekly doxorubicin vs doxorubicin alone
Design
Animal experimental study
Follow-up
4 weeks
Authors
Loading...
Requires human trials before any clinical consideration; leaves open costunolide's therapeutic potential in doxorubicin-treated patients.
Does costunolide prevent doxorubicin-induced cardiorenal toxicity in rats?
Costunolide demonstrates cardiorenal protective effects against doxorubicin-induced toxicity in a rat model by modulating oxidative stress, inflammation, and apoptosis.
Wen et al. (2022) studied Doxorubicin-induced cardiorenal toxicity. Costunolide vs. Doxorubicin alone was evaluated on Cardiorenal biochemical biomarkers, lipid profile, oxidative stress, inflammatory cytokines, and histological features. Costunolide significantly attenuated doxorubicin-induced cardiorenal toxicity, oxidative stress, inflammation, and apoptosis in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: